Found 366 results
Kasturi SPai, Kozlowski PA, Nakaya HI, Bürger MC, Russo P, Pham M, Kovalenkov Y, Silveira ELV, Havenar-Daughton C, Burton SL et al..  2017.  Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5α Restrictive Macaques.. J Virol. 91(4)
Caskey M, Schoofs T, Gruell H, Settler A, Karagounis T, Kreider EF, Murrell B, Pfeifer N, Nogueira L, Oliveira TY et al..  2017.  Antibody 10-1074 suppresses viremia in HIV-1-infected individuals.. Nat Med.
Freund NT, Wang H, Scharf L, Nogueira L, Horwitz JA, Bar-On Y, Golijanin J, Sievers SA, Sok D, Cai H et al..  2017.  Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller.. Sci Transl Med. 9(373)
Morris CD, Azadnia P, de Val N, Vora N, Honda A, Giang E, Saye-Francisco K, Cheng Y, Lin X, Mann CJ et al..  2017.  Differential Antibody Responses to Conserved HIV-1 Neutralizing Epitopes in the Context of Multivalent Scaffolds and Native-Like gp140 Trimers.. MBio. 8(1)
Nishimura Y, Gautam R, Chun T-W, Sadjadpour R, Foulds KE, Shingai M, Klein F, Gazumyan A, Golijanin J, Donaldson M et al..  2017.  Early antibody therapy can induce long-lasting immunity to SHIV.. Nature.
Ward AB, Wilson IA.  2017.  The HIV-1 envelope glycoprotein structure: nailing down a moving target.. Immunol Rev. 275(1):21-32.
McCoy LE, Burton DR.  2017.  Identification and specificity of broadly neutralizing antibodies against HIV.. Immunol Rev. 275(1):11-20.
Irimia A, Serra AM, Sarkar A, Jacak R, Kalyuzhniy O, Sok D, Saye-Francisco KL, Schiffner T, Tingle R, Kubitz M et al..  2017.  Lipid interactions and angle of approach to the HIV-1 viral membrane of broadly neutralizing antibody 10E8: Insights for vaccine and therapeutic design.. PLoS Pathog. 13(2):e1006212.
Behrens A-J, Harvey DJ, Milne E, Cupo A, Kumar A, Zitzmann N, Struwe WB, Moore JP, Crispin M.  2017.  Molecular Architecture of the Cleavage-Dependent Mannose Patch on a Soluble HIV-1 Envelope Glycoprotein Trimer.. J Virol. 91(2)
Escolano A, Dosenovic P, Nussenzweig MC.  2017.  Progress toward active or passive HIV-1 vaccination.. J Exp Med. 214(1):3-16.
Barouch DH, Thomas SJ, Michael NL.  2017.  Prospects for a Zika Virus Vaccine.. Immunity. 46(2):176-182.
Wibmer CKurt, Gorman J, Ozorowski G, Bhiman JN, Sheward DJ, Elliott DH, Rouelle J, Smira A, M Joyce G, Ndabambi N et al..  2017.  Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape.. PLoS Pathog. 13(1):e1006074.
Polonskaya Z, Deng S, Sarkar A, Kain L, Comellas-Aragones M, McKay CS, Kaczanowska K, Holt M, McBride R, Palomo V et al..  2017.  T cells control the generation of nanomolar-affinity anti-glycan antibodies.. J Clin Invest.
Bowen JR, Quicke KM, Maddur MS, O'Neal JT, McDonald CE, Fedorova NB, Puri V, Shabman RS, Pulendran B, Suthar MS.  2017.  Zika Virus Antagonizes Type I Interferon Responses during Infection of Human Dendritic Cells.. PLoS Pathog. 13(2):e1006164.
Locci M, Wu JE, Arumemi F, Mikulski Z, Dahlberg C, Miller AT, Crotty S.  2016.  Activin A programs the differentiation of human TFH cells.. Nat Immunol.
Liu J, Ghneim K, Sok D, Bosche WJ, Li Y, Chipriano E, Berkemeier B, Oswald K, Borducchi E, Cabral C et al..  2016.  Antibody-mediated protection against SHIV challenge includes systemic clearance of distal virus.. Science. 353(6303):1045-1049.
Moyer TJ, Zmolek AC, Irvine DJ.  2016.  Beyond antigens and adjuvants: formulating future vaccines.. J Clin Invest. 126(3):799-808.
Bournazos S, Gazumyan A, Seaman MS, Nussenzweig MC, Ravetch JV.  2016.  Bispecific Anti-HIV-1 Antibodies with Enhanced Breadth and Potency.. Cell. 165(7):1609-20.
Caskey M, Klein F, Nussenzweig MC.  2016.  Broadly Neutralizing Antibodies for HIV-1 Prevention or Immunotherapy.. N Engl J Med. 375(21):2019-2021.
Landais E, Huang X, Havenar-Daughton C, Murrell B, Price MA, Wickramasinghe L, Ramos A, Bian CB, Simek M, Allen S et al..  2016.  Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection Cohort.. PLoS Pathog. 12(1):e1005369.
Briney B, Le K, Zhu J, Burton DR.  2016.  Clonify: unseeded antibody lineage assignment from next-generation sequencing data.. Sci Rep. 6:23901.
von Bredow B, Arias JF, Heyer LN, Moldt B, Le K, Robinson JE, Zolla-Pazner S, Burton DR, Evans DT.  2016.  Comparison of Antibody-Dependent Cell-Mediated Cytotoxicity and Virus Neutralization by HIV-1 Env-Specific Monoclonal Antibodies.. J Virol. 90(13):6127-39.
Behrens A-J, Vasiljevic S, Pritchard LK, Harvey DJ, Andev RS, Krumm SA, Struwe WB, Cupo A, Kumar A, Zitzmann N et al..  2016.  Composition and Antigenic Effects of Individual Glycan Sites of a Trimeric HIV-1 Envelope Glycoprotein.. Cell Rep.
Lee J H, Ozorowski G, Ward AB.  2016.  Cryo-EM structure of a native, fully glycosylated, cleaved HIV-1 envelope trimer.. Science. 351(6277):1043-8.
Irimia A, Sarkar A, Stanfield RL, Wilson IA.  2016.  Crystallographic Identification of Lipid as an Integral Component of the Epitope of HIV Broadly Neutralizing Antibody 4E10.. Immunity. 44(1):21-31.